• Rani Therapeutics entered a May 26, 2026 securities purchase agreement for a $20 million registered direct offering of stock.
• Sale covers 12,476,637 Class A shares at $1.07 each, pre-funded warrants for 6,214,953 shares at $1.0699.
• Pre-funded warrants are immediately exercisable at $0.0001 per share, exercisable until fully used.
• Closing expected May 27, 2026, subject to customary conditions.
• H.C. Wainwright is lead placement agent; cash fee set at 6% of gross proceeds.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rani Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-239977), on May 27, 2026, and is solely responsible for the information contained therein.